OTCMKTS:RLMD
Relmada Therapeutics, Inc. Stock News
$3.83
+0.130 (+3.51%)
At Close: Apr 26, 2024
CORAL GABLES, Fla. , March 12, 2024 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announc
Relmada Therapeutics, Inc. (RLMD) Q3 2023 Earnings Call Transcript
02:56am, Thursday, 09'th Nov 2023
Relmada Therapeutics, Inc. (NASDAQ:RLMD ) Q3 2023 Results Earnings Conference Call November 9, 2023 4:30 PM ET Company Participants Tim McCarthy - Investor Relations, Advisors Sergio Traversa - Chief
Relmada Therapeutics to Report Third Quarter 2023 Financial Results and Host Conference Call and Webcast on November 8, 2023
07:30am, Friday, 03'rd Nov 2023
CORAL GABLES, Fla. , Nov. 3, 2023 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced
Relmada And REL-1017: Intriguing Underlying Efficacy In MDD Ahead Of Eventful 2024
07:50pm, Friday, 13'th Oct 2023
Phase 3 trial failures were due to abnormally high placebo responses driven by poor trial design, enrollment, and oversight. REL-1017's underlying efficacy appears robust, consistently reporting treat
Relmada Therapeutics to Present New Preclinical Data on its Psilocybin Program at AASLD The Liver Meeting® 2023
08:31am, Wednesday, 11'th Oct 2023
Low-dose psilocybin generated s tatistically significant reduc tions in liver fat content, plasma glucose levels and body weight gain in a mice model with high-fat-high-fructose diet (HFHFD)-induced m
CORAL GABLES, Fla. , Oct. 6, 2023 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced
Relmada (RLMD) Up on Positive Data for Anti-Depressant Candidate
03:02pm, Thursday, 21'st Sep 2023
Relmada's (RLMD) shares rise on long-term efficiency and safety data from the phase III study of its lead candidate REL-1017 to treat patients with major depressive disorder.
Relmada Therapeutics: Run Up Likely Into Phase 3 Results, Enhanced By Possible Interim Readout
06:53pm, Friday, 01'st Sep 2023
Relmada Therapeutics has provided updates on its phase 3 program of esmethadone (REL-1017) as an adjunct in major depressive disorder. An interim analysis could result in an early stoppage, it isn't a
Relmada Therapeutics to Participate in the Goldman Sachs Global Healthcare Conference
07:30am, Thursday, 08'th Jun 2023
CORAL GABLES, Fla. , June 8, 2023 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced
Relmada Therapeutics to Participate in the 2023 Jefferies Global Healthcare Conference
07:30am, Friday, 02'nd Jun 2023
CORAL GABLES, Fla. , June 2, 2023 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced
Relmada Therapeutics to Present Data at the American Society of Clinical Psychopharmacology 2023 Annual Meeting
07:30am, Wednesday, 24'th May 2023
CORAL GABLES, Fla. , May 24, 2023 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced
Relmada Therapeutics, Inc. (RLMD) Q1 2023 Earnings Call Transcript
09:10pm, Friday, 12'th May 2023
Relmada Therapeutics, Inc. (NASDAQ:RLMD ) Q1 2023 Earnings Conference Call May 11, 2023 4:30 PM ET Company Participants Tim McCarthy - LifeSci Advisors Sergio Traversa - Chief Executive Officer Cedric
Relmada Therapeutics to Report First Quarter 2023 Financial Results and Host Conference Call and Webcast on May 11, 2023
07:30am, Monday, 08'th May 2023
CORAL GABLES, Fla. , May 8, 2023 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced
Relmada Therapeutics, Inc. (RLMD) Q4 2022 Earnings Call Transcript
10:27pm, Thursday, 23'rd Mar 2023
Relmada Therapeutics, Inc. (NASDAQ:RLMD ) Q4 2022 Earnings Conference Call March 23, 2023 4:30 PM ET Company Participants Tim McCarthy - LifeSci Advisors Sergio Traversa - CEO Maged Shenouda - CFO Ced
CORAL GABLES, Fla. , March 17, 2023 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announc
